Newly diagnosed multiple myeloma in Taiwan: The evolution of therapy, stem cell transplantation and new treatment agents

Hematology/ Oncology and Stem Cell Therapy

Volumn 2, Issue 3, 2009, Pages 385-393

  Lin, Chung King ^a   Sung, Yung Chuan ^a  

^a CATHAY GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; PAMIDRONIC ACID; PREDNISONE; THALIDOMIDE; VINCRISTINE; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER STAGING; CHROMOSOME ANALYSIS; CLINICAL TRIAL; FLUORESCENCE IN SITU HYBRIDIZATION; HEALTH STATUS; HUMAN; LOW DRUG DOSE; MULTIPLE MYELOMA; STEM CELL TRANSPLANTATION; TAIWAN; TREATMENT OUTCOME; TREATMENT RESPONSE; MULTIMODALITY CANCER THERAPY;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; MULTIPLE MYELOMA; STEM CELL TRANSPLANTATION; TAIWAN;

EID: 77953669079     PISSN: 16583876     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1658-3876(09)50006-4     Document Type: Article

References (104)

1. Kyle RA, Therneau TM, Rajkumar SV JR, et al. A long-term study of prognosis of monoclonal gammopathy of undertermined significance. N Engl J Med. 2002;346:564-569.
2. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004; 351:1860-1873.
3. Huang SY, Yao M, Tang JL, et al. Epidemiology of multiple myeloma in Taiwan increasing incidence for the past 25 years and higher prevalence of extramedullary myeloma in patients younger than 55 years. Cancer. 2007;110:896-905.
4. Gonzalez D, Gonzalez M, Balanzategui A, et al. Molecular characteristics and gene segments usage in IgH gene rearrangements in multiple myeloma. Haematologica. 2005;90:906-913.
5. Kawano M, Hirano T, Matunda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myeloma. Nature. 1988;332:83-85.
6. Klein B, Zhang XG, Jourdan M, et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood. 1989;73:517-526.
7. Caligaris-Cappio F, Bergui L, Gregoretti MG, et al. Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood. 1991;77:2688-2693.
8. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improced survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516-2520.
9. Solly S. Remarks on the pathology of mollities ossium with cases. Med Chir Trans Lond 1844;27:435-61.
10. Blokhin N, Larionov L, Perevodchikova N, Chebotareva L, Merkulova N. Clinical experiences with sarcolysin in neoplastic diseases. Ann NY Acad Sci. 1958;68:1128-1132.
11. Hoogstraten B, Sheehe PR, Cuttner J, et al. Melphalan in multiple myeloma. Blood. 1967;30:74-83.
12. Mass RE. A comparison of the effect of prednisone and a placebo in the treatment of multiple myeloma. Cancer Chemother Rep. 1962;16:257-259.
13. Alexanian R, Haut A, Khan U, et al. Treatment for multiple myeloma, combination chemotherapy with different melphalan dose regimens. JAMA. 1969;208:1680-1685.
14. Lee BJ, Sahakian G, Clarkson BD, Krakoff IH. Proceedings: combination chemotherapy of multiple myeloma with alkeran, cytoxan, vincristine, prednisone, and BCNU. Cancer. 1974;33:533-538.
15. Case DC Jr, Lee DJ 3rd, Clarkson BD. Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M2 protocol. Am J Med. 1977;63:897-903.
16. McElwain TJ, Poweles RL. High-dose intravenous melphalan for plama-cell leukaemia and myeloma. Lancet. 1983;2:822-824.
17. Barlogie B, Alexanian R, Diche KA, et al. High-dose chemotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood. 1987;70:869-872.
18. Balogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refratory to alkylating agents. N Engl J Med. 1984;310:1353-1356.
19. Alexanian R, Barlogie B, Tucher S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol. 1990;33:86-89.
20. Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood. 1995;85:588-596.
21. Greipp PR, San Miguel J, Durie BGM, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412-3420.
22. Rajkumar SV. Thalidomide: tragic past and promising future. Mayo Clin Proc. 2004;79:893-903.
23. D'Amato RJ, Loughnan MS, Flynee E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994;91:4082-4085.
24. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P,Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeldis J, Barlogie B, Siegel D, Crowley J. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-1571.
25. Dimopoulos MA, Anagnostopoulos A, Weber D. Treatment of plasma cell dyscrasias with thalidomide and its derivatives. J Clin Oncol. 2003;21:4444-4454.
26. Adams J, Palombella VJ, Sausville EA, et al. Proteosome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999;59:2615-2622.
27. Ciechanover A. The ubiquitin-proteosome proteolytic pathway. Cell. 1994;79:13-21.
28. Von Meltzer I, Krebbel H, Hecht M, et al. Bortezomib inhibit human osteoclastogenesis. Leukemia prepublished on June 21, 2007, as DOI 10.1038/sj.leu.2404806.
29. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase 1 trial of the proteosome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol. 2002;20:4420-4427.
30. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609-2617.
31. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487-2498.
32. Harousseau JL, Attal M, Leleu X, et al. Bortezomib plus dexamethasone as induction treatment priot to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica. 2006;91:1498-1505.
33. Harousseau JL, Mathiot C, Attal M, et al. Velcade/ dexamethasone (Vel/D) versus VAD as induction treatment prior to autologous stem cell transplant (ASCT) in newly diagnosed multiple myeloma (MM ): updated results of the IFM 2005/01 trial. Blood. 110:450 (abstract).
34. Richardson PG, Sonneveld P, Schuster MW, et al. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol. 2007;137:429-435.
35. Jagannath S, Richardson PG, Sonneveld P, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leuk. 2007;21:151-157.
36. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002;100:3063-3067.
37. Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006;108:3458-3464.
38. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123-2132.
39. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed or refracttory multiple myeloma in North America. N Engl J Med. 2007;357:2133-2142.
40. Coleman RE. Bisphosphonates: clinical experience. Oncologist. 2004;9(suppl 4):14-27.
41. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer. 2000;82:1459-1468.
42. Yaccobs S, Pearse RN, Johnson CL, et al. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol. 2002;116:278-290.
43. Dhodapkar MV, Singh J, Mehta J, et al. Anti-myeloma activity of pamidronate in vivo. Br J Haematol. 1998;103:530-532.
44. Vincenzi B, Santini D, Dicuonzo G, et al. Zoledronic acid related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res. 2005;25:144-151.
45. Berensen JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer. 2001;91:1191-1200.
46. Aviles A, Nambo MJ, Neri N, et al. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol. 2007;24:227-230.
47. Teoh G. Asia-Pacific Dazzle study for newly-diagnosed myeloma. 13th Cogress of the Acia-Pacific blood and Marrow transplantation. 2008;29(abstract 0-1-7).
48. a (abstract).
49. Dispenzieri A, Rajkumar SV, Gertz MA, et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMA RT): consensus statement. Mayo Clin Proc. 2007;82:323-341.
50. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood. 2007;109:3489-3495.
51. Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101:4569-4575.
52. Shaughnessy JDJr, Zhan F, Berington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109:2276-2284.
53. Decaux O, Lode L, Magrangeas F, et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients. A study of the Intergroupe Francophone du Myelome. J Clin Oncol. 2008;26:4798-4805.
54. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Cancer. 1975;36:842-854.
55. Merlini G, Waldenstrom JG, Jagakar SD. A new improved clinical staging system for multiple myeloma base on analysis of 123 treated patients. Blood. 1980;55:1011-1019.
56. San Miguel JF, Garcia-Sanz R, Gonzalez M, et al. A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood.1995;85:448-455.
57. Jacobson J, Hussein M, Barlogie B, Durie BG, Crowley JJ. A new staging system for multiple myeloma based on the Southwest Oncology Group (SWOG) experience. Br J Haematol. 2003;122:441-450.
58. Avet-Loisseau H, Andree-Ashley LE, Moore D, et al. Molecular cytogenetic abnormalities in multiple myeloma and plasma cell leukemia measured using comparative genomic hybridization. Genes Chromosomes Cancer. 1997;19:124-133.
59. Dewald GW, Kyle RA, Hicks GA, et al. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood. 1985;66:380-390.
60. Tricot G, Barlogie B, Jagannath S, et al. Poor prognosis in multiple myeloma is associated with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood. 1995;86:4250-4256.
61. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Frabcis du Myelome. N Engl J Med. 1996; 335:91-97.
62. Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemotherapy for multiple myeloma: final results of the phase III US Intergroup trial S9321. J Clin Oncol. 2006;24:929-936.
63. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem cell transplantation for multiple myeloma. N Engl J Med. 2003;349:2495-2502.
64. Blade J. Transplantation for multiple myeloma. Who, when, how often? Blood. 2003;112:3465-3477.
65. Fermand JP, Chevret S, Ravaud P, et al. High-dose chemotherapy and autologous blood stem cell transplantation in multiple myeloma: Results of a phase II trial involving 63 patients. Blood. 1993;82:2005-2009.
66. Barlogie B, Jagannath S, Deskin, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999;93:55-65.
67. Lenhoff S, Hjorth M, Holmberg E, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: A population-based study. Nordic Myeloma Study Group. Blood. 2000;95:7-11.
68. Fermand JP, Katschian S, Divine M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: Long term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol. 2005;23:9227-9233.
69. San Miguel JF, Lahuerta JJ, Garcia-Sanz R, et al. Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematol J. 2000;1:28-36.
70. Morris CL, Siegel E, Barlogie B, l. et al. Mobilization of CD 34+ cells in elderly patients (>/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol. 2003;120:413-423.
71. Bardos A, Barlogie B, Siegel E, et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol. 2002;20:1295-1303.
72. Rosinol L, Perez-Simon JA, Sureda A, et al. A prospective PE THEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood. 2008;112:3591-3593.
73. Barlogie B, van Rhee F, Shaughnessy JD Jr, et al. Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood. 2008;112:3122-3125.
74. San-Miguel J, Harousseau J-L, Joshua D, et al. Individualizing treatment of patients with myeloma in the era of novel agents. J Clin Oncol. 2008;26:2761-2766.
75. Rajkumar SV, Hagman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005;106:4050-4053.
76. a.
77. a(abstract).
78. Kumar S, Dispenzieri A, Lacy MQ, et al. Impact of lenalidomide therapy on stem cell mobilization and engrafment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leuk. 2007;21:2035-2042.
79. Rajkumar SV, Blood E, Vesole DH, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24:431-436.
80. Rajkumar SV, Rosinol L, Hussein M, et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myelom. J Clin Oncol. 2008;26:2171-2177.
81. Lokhorst HM, Schmidt-Wolf I, Sonneveld P, et al. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica. 2008;93:124-127.
82. Myeloma Trialists' Collaborative Group. Combination chemotherapy vs melphalan plus prednisone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomized trials. J Clin Oncol. 1998;16:3832-3842.
83. Facon T, Mary JY, Hulin C, et al, on behalf of the Intergroupe Francophone du Myélome. Melphalan and prednisone plus thalidomide vs melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomized trial. Lancet. 2007;370:1209-1218.
84. Palumbo A, Bringhen S, Caravita T, et al, for the Italian Multiple Myeloma Network, GIMEMA. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006;367:825-831.
85. Hulin C, Virion J, Leleu X, et al, Intergroupe Francophone du Myelome. Comparison of melphalan-prednisone-thalidomide (MP-T) to melphalan prednisone (MP) in patients 75 years of age or older with untreated multiple myeloma (mm). Preliminary results of the randomized, double-blind, placebo controlled IFM 01-01 trial (abstract). J Clin Oncol. 2007;25:8001.
86. Palumbo A, Bringhen S, Liberati AM, et al. Oral melphalan, prednisone and thalidomide in elderly patients with multiple myeloma: update results of a randomized controlled trial. Blood. 2008;112:3107-3114.
87. Palumbo A, Falco P, Corradini P, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed multiple myeloma: a report from GIMEMA Italian Multiple Myeloma Network. J Clin Oncol. 2007;25:4459-4465.
88. Garban F, Attal M, Michallet M, et al, for the Intergroupe Francophone du Myélome and the Swiss Group for Clinical Cancer Research. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM 99-03 trial) with tandem autologous stem cell transplantation (IFM 99-04 trial) in high-risk de novo multiple myeloma. Blood. 2006;107:3474-3480.
89. Alexanian R, Geban E, Haut A, et al. Unmaintained remissions in multiple myeloma. Blood. 1978;51:1005-1011.
90. Durie BG, Kyle RA, Belch A, et al. Myeloma management guidelines: a consensus report from the scientific advisors of the International Myeloma Fouindation. Hematol J. 2003;4:379-398.
91. Abdelkefi A, Ladeb S, Torjman L, et al. Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood. 2008;111:1805-1810.
92. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic cell transplantation for multiple myeloma. N Engl J Med. 2006;354:1021-1030.
93. Bruno B, Rotta M, Patricca F, et al. A comparison of allografting with autografting for newly diagnosed multiple myeloma. N Engl J Med. 2007;356:1110-1120.
94. Sagaster V, Ludwig H, Kaufmann H, et al. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13 q- deletion. Leuk. 2007;21:164-168.
95. SanMiguel JF, Richardson PG, Sonneveld P, et al. Bortezomib in renally impaired multiple myeloma patients. Haematologica. 2007;92:1114.
96. Chanan-Khan AA, Kaufman JL, Mehta J, et al. Activity and safety of bortemzomib in multiple myeloma patiets with advanced renal failure: a multicenter retrospective study. Blood. 2007;109:2604-2606.
97. Bergsagel D. The incidence and epidemiology of plasma cell neoplasms. Stem Cells. 1995;Suppl 2:1-9.
98. Lin TL, Shih LY, Dunn P, et al. Immunoglobulin D multiple myeloma. Chang Gung Med J. 2000;23:451-457.
99. Lee LN, Jan IS, Tien HF, et al. Laboratory and clinical characterization of monoclonal gammopathy in Taiwanese. J Formos Med Assoc. 2002;101:91-97.
100. Lin JC, Lee JY, Lin CK. Multiple myeloma, a case presentation with discussion. Med Today. 1988;15:419-423.
101. Lin CK. Monoclonal gammopathy and multiple myeloma. J Intern Med Taiwan. 1990;1:57-62.
102. Huang SY, Yao M, Tang JL, et al. Clinical significance of cytogenetics and interphase fluorescence in situ hybridization analysis in newly diagnosed multiple myeloma in Taiwan. Ann Oncol. 2005;16:1530-1538
103. Deng SH, Xu Y, Wang YF, et al. Cytogenetic characteristics of patients with multiple myeloma in China: analysis of 100 case. Zhonghua Yi Xue Za Zhi. 2007;87:1685-1688.
104. Chiou TJ, Wang TH, Chao TY, et al. Randomized Phase II trial of thalidomide alone versus thalidomide plus interferon alpha in patients with refractory multiple myeloma. Cancer Invest. 2007;25:140-147.